Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Foundation Inc

Neither a doctor nor a teaching hospital

Research payments

$254,637

45 payments

Through program year 2025, Clinical Research Foundation Inc is reported as receiving $254,637 in research payments, across 45 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $30,369 5
2024 Research $47,026 2
2023 Research $3,941 1
2022 Research $20,471 4
2021 Research $77,228 14
2020 Research $41,428 10
2019 Research $34,174 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $72,599 11 payments
  2. AstraZeneca Pharmaceuticals LP $47,026 2 payments
  3. Kowa Research Institute, Inc. $38,013 5 payments
  4. Pfizer Inc. $33,676 11 payments
  5. Genentech, Inc. $25,837 4 payments
  6. AbbVie, Inc. $25,632 5 payments
  7. Novo Nordisk AS $11,854 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. K-877-302 $38,013 5 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $32,495 5 payments
  3. A Phase 2 Multicenter Randomized Parallel-Arm Placebo-Controlled Study of Ly3074828 in Subjects With Active Crohns Disease (Serenity) $27,157 2 payments
  4. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $26,838 1 payment
  5. UC P3: Double-Blind Treat Straight Through $25,837 4 payments
  6. A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) $20,188 1 payment
  7. Serotype Distribution of Streptococcus Pneumonia in Communityacquired Pneumonia in Hospitalized Adults 18 Years of Age in the United States $13,906 1 payment
  8. Ex9536-4388 $11,854 7 payments
  9. Diarrhea Burden in Adults in the United States Attributable to Clostridioides Difficile An Active Surveillance Study in Louisville $9,918 3 payments
  10. Epidemiology of Clostridium Difficile Infection in the United States A Prospective Study Low Interventional Study Lis1 $9,851 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record